Supply Update

Availability of Hiprex 1g Tablets


Overview


MEDA Pharmaceuticals Ltd, a Mylan company, the marketing authorisation holder for Hiprex in the UK; is currently experiencing a temporary supply constraint of Hiprex 1g tablets.

Latest Supply Status


We are experiencing a temporary supply constraint of Hiprex 1g tablets and anticipate normal stock levels to resume over the coming months.

Currently supplies will vary from pharmacy to pharmacy and may not always be available.

With patient access our priority, we will continue to proactively provide updates on our website regarding any changes in stock availability.

Ongoing Supply Management


Mylan is working diligently to manage supply and expediting where possible to alleviate the situation and achieve a steady state of supply as expeditiously as possible.

Information for Patients


Mylan is unable to make any specific treatment recommendations to patients. Patients should speak to their healthcare provider to discuss treatment options according to their health needs and their relevant clinical history.

Reporting of side effects

If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at http://www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine. You should also report any side effects to Mylan UK Pharmacovigilance on +44 (0)800 121 8267 or ukpharmacovigilance@mylan.com.

About Hiprex


Hiprex is indicated in the prophylaxis and treatment of urinary tract infections.

Resources


Hiprex SmPC (summary of product characteristics)         Hiprex Patient Information Leaflet

Contact Information


Mylan Medical Information team can be contacted via the Mylan switch board on 01707 853000.



HIP-2018-0003
DOP: DECEMBER 2018